The short version of animal model fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-12-31 and is reviewed periodically as new material appears.
Several mechanisms have been proposed to explain the activity observed in animal models. The most frequently cited involve signaling through vascular endothelial growth factor receptor 2 and modulation of the nitric oxide system. Researchers have also described interactions with protective pathways in the gut lining. These proposed mechanisms appear in the literature as hypotheses supported by preclinical observations, not as confirmed pathways in humans. The precise way the peptide produces its reported effects, and whether those effects carry across species, remain areas of active and unresolved investigation.
BPC-157 is a synthetic pentadecapeptide, meaning it consists of fifteen amino acids joined in a single chain. Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, a fragment corresponding to part of a larger protein found in human gastric juice. The peptide was first described in the 1990s by researchers in Zagreb who were studying gastric protective factors. It is not a naturally circulating hormone; it is a laboratory-made fragment derived from a stomach protein. The name is an abbreviation of body protection compound, with the number referring to the fragment's position in the source protein.
Most published work on BPC-157 consists of preclinical studies, including rodent models of tissue injury, gastrointestinal lesions, and vascular or tendon damage, together with in vitro cell assays. Reviews frequently note that the mechanisms proposed in these papers remain incompletely characterised and that findings have not been confirmed in large randomised human trials. The compound is widely sold as a research chemical rather than a licensed medicine, and labels commonly carry a statement that it is not for human use. Whether any of the reported animal effects translate to humans is an open question rather than an established result.
Terminology in the literature is not fully standardised. Papers and product listings use BPC-157, BPC 157, and the longer phrase stable gastric pentadecapeptide BPC 157 interchangeably, and synonyms such as bepecin or PL 14736 appear in older or company-linked publications. Purity claims and reported masses can also differ between sources because peptide preparations may include counterions, residual solvents, or bound water. This variability complicates direct comparison of results across studies and makes the exact identity and grade of a given sample worth verifying. Discussions of the compound should therefore specify the source, salt form, and stated purity where those are known.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic pentadecapeptide | Composed of fifteen amino acid residues |
| Amino acid sequence | Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val | Single-letter form GEPPPGKPADDAGLV |
| Original source | Fragment of a protein in human gastric juice | First characterized in the 1990s |
| Number in name | 157 | Refers to the fragment's position in the source protein |
| Human trial evidence | Limited | Preclinical rodent data predominate |
BPC 157 is a synthetic peptide built from fifteen amino acids. The letters stand for body protection compound, and the number is a laboratory code rather than a description of any biological feature. Its single-letter sequence is GEPPPGKPADDAGLV, which corresponds to a calculated mass near 1419.5 daltons. The material is produced by solid-phase peptide synthesis and is distributed as a lyophilized powder, not as a purified extract from a natural source.
Early work on this family of molecules examined fractions of human gastric juice, where a larger protein was reported to protect gastrointestinal tissue in animal models. BPC 157 was designed as a shorter, more stable fragment of that protein and then studied on its own. The peptide itself is not a normal dietary component and is not present in the human body in meaningful quantities. Descriptions of its origin therefore refer to the research lineage of a laboratory molecule rather than to an endogenous or nutritional substance.
Lyophilized peptide powder is generally stored at minus twenty degrees Celsius or lower and kept away from light and moisture. Under these conditions degradation is slow, and sealed vials remain stable for extended periods. Once dissolved, the material is less stable, particularly in aqueous buffers near neutral pH, where hydrolysis and oxidation proceed faster. Solutions are usually kept cold and used within days to weeks. Repeated freeze-thaw cycles are avoided because they encourage aggregation.
Identity and purity are established using reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities and yields a percentage purity. Mass spectrometry, typically with electrospray ionization, confirms the molecular mass against the expected value. Amino acid analysis or peptide mapping provides additional sequence confirmation. These methods are complementary, since chromatography measures how much material is present while mass spectrometry verifies what that material is. A certificate of analysis normally reports both.
Analytical results depend on the column, gradient, and detector wavelength chosen by the laboratory, so purity values from different sources are not always directly comparable. Water content, counterion form, and residual trifluoroacetate affect both mass and purity calculations. Microbiological and endotoxin testing are separate from chemical purity and are not covered by a standard chromatographic run. Buyers evaluating a material typically request the full method description rather than a single purity figure.
Proposed mechanisms in the literature involve the nitric oxide system, vascular endothelial growth factor signaling, and epidermal growth factor receptor pathways. Some studies report changes in blood vessel formation or in inflammatory mediators, while others describe interactions with nervous tissue. Much of this evidence rests on molecular markers in cultured cells or animal models. Whether the same pathways operate the same way in humans has not been established. Authors therefore tend to describe mechanisms as hypothetical rather than settled.
Direct human evidence is scarce. One trial in ulcerative colitis delivered the compound by enema and produced limited publicly reported results without a clear benefit. The compound is not an approved medicine in most jurisdictions. In many markets it is sold as a research chemical; in others it falls under prescription or controlled categories. Regulators have not confirmed any claimed medical use, and product labels rarely undergo premarket review.
Some properties, such as the peptide's sequence and molecular mass, are firmly established. Other claims, particularly about mechanism and clinical benefit, remain open questions. Proposed mechanisms include effects on nitric oxide signaling and on cell migration, but these are hypotheses supported by limited evidence. Reviewers often note that the field lacks large controlled human trials. Positive animal findings are best treated as signals for further study rather than as settled conclusions.
Most published studies examine BPC-157 in animal models rather than in humans. Common subjects include rats and mice, and researchers often use models of tissue injury, surgery, or induced inflammation. Reported endpoints include healing rates, blood vessel formation, and markers of tissue repair. These designs provide controlled comparisons, but findings in animals do not automatically transfer to people. Human clinical data remain limited and are frequently described as preliminary.
Doses in the literature are usually expressed in micrograms or nanograms per kilogram of body weight. Investigators have administered the peptide by several routes, including injection and oral delivery, depending on the question asked. Route and dose vary widely across studies, which complicates direct comparison of results. Many papers report effects at low doses, but the absence of a standardized protocol limits generalization. Reporting practice differs between research groups.
In April 2018, Boston Market announced that it was expanding its menu to offer rotisserie prime rib nationwide, three days a week. In 2019, the chain closed 45 locations, with one report noting competition with rotisserie chickens sold at regular supermarket chains. In 2020, it introduced baby back ribs paired with Sweet Baby Ray's sauce. In April 2020, Sun Capital Partners sold Boston Market to Engage Brands, LLC, a company of Rohan Group, owned by Jignesh "Jay" Pandya. This started a difficult period in which the company stopped paying its suppliers, rent, and some employees. This resulted in over 150 lawsuits. In 2023, New Jersey shut down 27 locations when it was determined employees were owed hundreds of thousands of dollars. The chain started with about 300 locations at the start of 2023, but was down to 79 locations later that year, and by early 2024 there were fewer than 30 locations even though the chain opened a new location in India.
=== Pharmacokinetics === Following oral administration, dextromethorphan is rapidly absorbed from the gastrointestinal tract, where it enters the bloodstream and crosses the blood–brain barrier. At therapeutic doses, dextromethorphan acts centrally (meaning that it acts on the brain) as opposed to locally (on the respiratory tract). It elevates the threshold for coughing, without inhibiting ciliary activity. Dextromethorphan is rapidly absorbed from the gastrointestinal tract and converted into the active metabolite dextrorphan in the liver by the cytochrome P450 enzyme CYP2D6. The average dose necessary for effective antitussive therapy is between 10 and 45 mg, depending on the individual. The International Society for the Study of Cough recommends "an adequate first dose of medication is 60 mg in the adult and repeat dosing should be infrequent rather than qds recommended." Dextromethorphan has an elimination half-life of approximately four hours in individuals with an extensive metabolizer phenotype; this is increased to approximately 13 hours when dextromethorphan is given in combination with quinidine. The duration of action after oral administration is about three to eight hours for dextromethorphan hydrobromide, and 10 to 12 hours for dextromethorphan polistirex. Around one in ten of the Caucasian population has little or no CYP2D6 enzyme activity, leading to long-lived high drug levels.
== Prevalence == Over 30% of athletes participating in 2011 World Championships in Athletics admitted having used banned substances during their careers. According to a study commissioned by the World Anti-Doping Agency (WADA), actually 44% of them had used them. Nevertheless, only 0.5% of those tested were caught. The entire Russian track and field team was banned from the 2016 Olympic Games, as the Russian State had sponsored and essentially sanctioned their doping program.
Once drug shipments have been seized by the CMF navies, vessels and crew are free to go, and there have therefore been no prosecutions of foreign flagged or stateless vessels involved in drug trafficking on the high sea of the WIO. This is problematic as it does not prevent the crew and vessel from returning with a new shipment. Capacity building initiatives, funded by countries such as the United States and India aim to improve security capabilities among small island states and coastal states. The support and presence of these states may however also stem from a geopolitical context, with the increasing presence of China in the WIO.
Sources: en.wikipedia.org
Many libraries utilize peptide chains much shorter than 70 amino acids. For 20 encoded amino acids at maximally 70 positions, this results in an upper limit of 2070, or more than 10 quindecillion (1×1091), possible combinations, not accounting for the potential use of amino acids with post-translational modifications or amino acids not encoded in the genetic code, such as selenocysteine and pyrrolysine. Peptide libraries generally encompass only a fraction of this diversity, selected for depending on the needs of the experiment, for instance keeping some amino acids constant at certain positions. Large random peptide libraries are often used for the synthesis of certain peptide molecules, such as ultra-large chemical libraries for the discovery of high-affinity peptide binders. Any increase in the library size severely affects parameters, such as the synthesis scale, the number of library members, the sequence deconvolution and peptide structure elucidation. To mitigate these technical challenges, an algorithm-supported approach to peptide library design may use molecular mass and amino acid diversity to simplify the laborious permutation identification in complex mixtures when using mass spectrometry. This approach is used to avoid mass redundancy. Biological reagent companies, such as Pepscan, ProteoGenix, Mimotopes, GenScript and many others, manufacture customized peptide libraries.
Agreement between Great Britain and Portugal for regulation of the opium monopolies of the colonies of Hong Kong and Macao. London, Printed for H.M. Stationery office. by Harrison and sons, ltd. Forbes, Andrew; Henley, David (2011). Traders of the Golden Triangle. Chiang Mai: Cognoscenti Books. ASIN B006GMID5K Great Britain, India office (1922). The truth about Indian opium. [London] Printed by H.M. Stationery Off. Hai guan zong shui wu si shu (1889). The poppy in China. Shanghai; Statistical Dept. of the Inspectorate General of Customs. Hideyuki Takano; The Shore Beyond Good and Evil: A Report from Inside Burma's Opium Kingdom (2002, Kotan, ISBN 0-9701716-1-7) Inglis, Lucy, Milk of Paradise: A History of Opium, Pan Macmillan, London, 2018. **Review: Julie Peakman: "Not Just Smelling the Flowers", History Today History Today Vol. 68/10, October 2018, pp. 102–103. Latimer, Dean, and Jeff Goldberg with an Introduction by William Burroughs. Flowers in the Blood: The Story of Opium. New York: Franklin Watts, 1981 MacPherson, Duncan (1843). Two years in China. Narrative of the Chinese expedition, from its formation in April, 1840, to the treaty of peace in August, 1842. London, Saunders. Martin, Steven. The Art of Opium Antiques. Chiang Mai: Silkworm Books, 2007. Photographs and history of Chinese and Vietnamese opium-smoking paraphernalia. McCoy, Alfred W. The Politics of Heroin: CIA Complicity in the Global Drug Trade. New York: Lawrence Hill Books, 1991. Merwin, Samuel (1907).
India imports around half of its crude oil from Middle Eastern countries. On 27 March, the Indian government reduced excise duties on petrol and diesel by ₹10 (10¢ US) per litre to keep fuel prices from rising. Unfounded panic about shortages led to people forming long queues for petrol. India is the 4th largest country in the world by oil refining capacity and throughput. Indian refiners started buying petroleum from Russia as the war disrupted supplies from the Middle East. To ensure domestic availability of fuel, the government raised export duties to ₹21.5 (22¢ US) per litre on diesel and to ₹29.5 (31¢ US) per litre on aviation fuel. Liquefied petroleum gas (LPG) is the main cooking fuel for households and restaurants in India. 60% of India's LPG demand is fulfilled by imports, most of which pass through the Hormuz Strait. It was the first fuel to be affected by the crisis, leading to long queues and delayed deliveries. Many people are using fuels like kerosene, coal and wood as stopgap measures. In the month of March 2026, India installed piped gas connections to 580,000 new households. Piped gas in India is mainly sourced from domestic gas fields, therefore its supply was unaffected by the war. Nearly 75% of electricity in India is generated from coal. India plans to increase coal power to meet high energy demands in the summer amid the oil and gas crisis. In Gujarat state, the gas shortage has led to its ceramics industry shutting down. In Mumbai, many restaurants shut down fully or partially in early March, due to the lack of cooking gas.
Sources: en.wikipedia.org
== Dihydrogen bond == The hydrogen bond can be compared with the closely related dihydrogen bond, which is also an intermolecular bonding interaction involving hydrogen atoms. These structures have been known for some time, and well characterized by crystallography; however, an understanding of their relationship to the conventional hydrogen bond, ionic bond, and covalent bond remains unclear. Generally, the hydrogen bond is characterized by a proton acceptor that is a lone pair of electrons in nonmetallic atoms (most notably in the nitrogen, and chalcogen groups). In some cases, these proton acceptors may be pi-bonds or metal complexes. In the dihydrogen bond, however, a metal hydride serves as a proton acceptor, thus forming a hydrogen-hydrogen interaction. Neutron diffraction has shown that the molecular geometry of these complexes is similar to hydrogen bonds, in that the bond length is very adaptable to the metal complex/hydrogen donor system.
Candesartan is administered clinically as the cyclohexyl 1-hydroxy ethyl carbonate ester, known as candesartan cilexetil. It is a cascading prodrug that is completely metabolised by esterases in the intestinal wall during absorption, releasing the active candesartan moiety. In the first step of the activation process, the carbonate group is hydrolyzed, releasing carbon dioxide. This reaction also produces cyclohexanol, a relatively non-toxic byproduct that contributes to the favorable safety profile of the prodrug. Another side product of the cascading mechanism is acetic acid, derived from the hydrolysis of the O-CH(CH3)- group; like cyclohexanol, it is also non-toxic and poses minimal risk during drug activation. The use of the prodrug form, candesartan cilexetil, enhances the bioavailability of candesartan. However, its absolute bioavailability remains relatively low, ranging from approximately 15% when administered as tablets to 40% as an oral solution. Candesartan has an IC50 of 15 μg/kg. The active form of candesartan is not used directly in clinical practice, as it would require higher dosing and is associated with a less favorable adverse event profile.
Around 90% of the protein structures available in the Protein Data Bank have been determined by X-ray crystallography. This method allows one to measure the three-dimensional (3-D) density distribution of electrons in the protein, in the crystallized state, and thereby infer the 3-D coordinates of all the atoms to be determined to a certain resolution. Roughly 7% of the known protein structures have been obtained by nuclear magnetic resonance (NMR) techniques. For larger protein complexes, cryo-electron microscopy can determine protein structures. The resolution is typically lower than that of X-ray crystallography, or NMR, but the maximum resolution is steadily increasing. This technique is still a particularly valuable for very large protein complexes such as virus coat proteins and amyloid fibers. General secondary structure composition can be determined via circular dichroism. Vibrational spectroscopy can also be used to characterize the conformation of peptides, polypeptides, and proteins. Two-dimensional infrared spectroscopy has become a valuable method to investigate the structures of flexible peptides and proteins that cannot be studied with other methods. A more qualitative picture of protein structure is often obtained by proteolysis, which is also useful to screen for more crystallizable protein samples. Novel implementations of this approach, including fast parallel proteolysis (FASTpp), can probe the structured fraction and its stability without the need for purification.
Sources: en.wikipedia.org
It is a chain of fifteen amino acids, referred to as a pentadecapeptide. The sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It corresponds to a fragment of a protein found in human gastric juice.
It is neither a naturally circulating hormone nor an approved medicine in most countries. It is a synthetic peptide fragment used chiefly as a laboratory research material. Its regulatory status varies by jurisdiction, and it is not authorized as a therapeutic product in the United States or the European Union.
Published human evidence is very limited. Most findings come from rodent studies conducted by a small number of groups. As a result, statements about its effects in humans are generally described as uncertain rather than established.
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence corresponds to a fragment of a protein found in human gastric juice. It is studied mainly in preclinical research and is not an approved pharmaceutical product in major markets. Materials sold for laboratory use are typically labelled as research chemicals.